Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Oxaliplatin

Leucovorin

Fluorouracil

Apatinib

Immunomodulating Agents

Protein Kinase Inhibitors

Enzyme Inhibitors

Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times

FOLFOX-HAIC

Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.

Camrelizumab

Apatinib was administered orally 250mg once per day

Ming Shi, MD

Compare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab plus apatinib in hepatocellular carcinoma with portal vein invasion.

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma With Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

the The date of randomization to death from any cause

The date from randomization until progression according to RECIST 1.1 or death. from any cause

The time from randomization until first evidence of disease progression.

The time from initiating treatment to achieve complete or partial response according to RECIST 1.1

The time from randomization to disease progression or death in patients who achieve complete or partial response according to RECIST 1.1

The proportion of patients with the best response of complete response or partial response according to RECIST 1.1

The proportion of patients with the best response of complete response, partial response and stable disease according to RECIST 1.1

Spots Global Cancer Trial Database for hepatocellular carcinoma, hepatic arterial infusion chemotherapy, immunotherapy, targeted therapy